Regulatory navigator

FDA regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) on two tiers. Which tier you are in decides almost everything else.

Section 361 HCT/PSection 351 biologic
Legal basisPHS Act §361; 21 CFR Part 1271PHS Act §351 and FD&C Act; 21 CFR Parts 312, 600–680, plus 1271
Premarket reviewNoneIND for clinical trials, then BLA approval
Typical examplesBone, skin, corneas, minimally manipulated cord blood for related-donor useCulture-expanded MSCs, CAR-T, gene-modified HSCs, unrelated cord blood (licensed HPC products)
Where customized stem cell therapy usually landsRarelyAlmost always

Self-check: 361 or 351?

A product is a 361 HCT/P only if it meets all four criteria in 21 CFR 1271.10(a).

0 of 4 criteria answered

Step 0. Same surgical procedure exception (21 CFR 1271.15(b))

Are cells removed from a patient and put back into the same patient during the same surgical procedure, with no processing beyond rinsing, cleansing, sizing or shaping?

Criterion 1. Minimal manipulation

Does processing leave the cells' or tissue's relevant biological characteristics unchanged? Culture expansion, genetic modification, activation or enzymatic digestion to isolate cells usually go beyond minimal manipulation.

Criterion 2. Homologous use only

Will the cells perform the same basic function in the recipient as in the donor (for example, cord blood stem cells used to rebuild the blood system), as shown by the labeling and advertising?

Criterion 3. No combination with another article

Is the product made without combining it with another article, apart from water, crystalloids, or a sterilizing, preserving or storage agent that raises no new safety concern?

Criterion 4. Systemic effect and metabolic activity

Either the product has no systemic effect and does not depend on living cells' metabolic activity for its main function, OR it is for autologous use, use in a first- or second-degree blood relative, or reproductive use. Answer Yes if one of these is true.

This self-check is for education only and does not replace an FDA determination.

Key points for researchers

  • "Personalized" or "autologous" does not by itself make a product exempt. Manipulation and intended use decide the tier.
  • Federal courts have repeatedly upheld FDA's authority over clinic-made stem cell products such as SVF.
  • FDA's January 2026 statements on flexible CMC oversight for cell and gene therapies apply to sponsors working inside the IND/BLA system, not to unapproved clinic products.